Background: Concurrent chemoradiotherapy (CCRT) is superior to radiotherapy alone for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Whether adding induction chemotherapy (IC) further improves the outcome warrants investigation.
Introduction
Radiotherapy (RT) is the mainstay of NPC treatment. Longer survival and milder toxicity have been achieved as RT techniques have evolved from two-dimensional radiotherapy (2DRT) to three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The Intergroup 0099 study is the first trial to demonstrate the benefit of chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) [1] . Using chemotherapy during and after RT is currently the preferred treatment. Nevertheless, in endemic areas, randomised studies with the same design had inconsistent results. Meta-analyses have shown that concurrent chemoradiotherapy (CCRT) improves disease control and overall survival (OS); however, adjuvant chemotherapy (AC) has been demonstrated to have no beneficial effects [2] . A randomised phase III study directly tested the effect of adding AC to CCRT and revealed that both arms had similar outcomes [3] . Induction chemotherapy (IC) does not improve OS but can enhance locoregional and distant control. A treatment strategy involving IC-CCRT is an appealing option, particularly for patients with extensive locoregional disease infiltrating or abutting critical structures.
Mitomycin C-based regimens have been studied in recurrent metastasis [4] [5] [6] and induction [7] settings and have shown a high response rate and long survival, respectively. Based on these results, we explored the effect of adding induction mitomycin C, epirubicin, cisplatin, and 5-fluorouracil (5-FU)/leucovorin (MEPFL) [7] to CCRT in LANPC patients in a phase III trial. According to the fifth and sixth edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system, the 5-year disease-free survival (DFS) of patients with stage III NPC is higher than 80% [8] . Therefore, only patients with stage IVA and IVB were recruited.
Patients and methods

Study design, eligibility, and randomization
This was a multicenter parallel group randomised phase III study [Taiwan Cooperative Oncology Group (TCOG) 1303]. The primary end point was DFS, defined as the time from randomization to first failure or death from any cause. The 5-year DFS rate of patients receiving CCRT was estimated to be 50% [9] , and induction could increase the rate to 63%. Under the assumptions of exponential survival functions, a total sample size of up to 480 patients should be enrolled and followed-up for a minimum 1.5 years to reach 80% power for detecting the 13% improvement in the 5-year DFS rate attributable to additional IC by using a twosided log-rank test with a type I error rate of 5% and two interim looks. The sample size was verified using the software East (2000) in two interim analyses by using the O'Brien-Fleming boundary for early rejection of the null hypothesis. Sample size re-evaluation was not planned during this study.
Patients with histologically proved stage IVA or IVB NPC (fifth edition of the AJCC/UICC staging system, 1997), age <70 years, an Eastern Cooperative Oncology Group performance status 1, normal hemogram, renal, and liver function were randomised to receive CCRT with or without induction MEPFL by the TCOG. Before randomization, patients signed informed consent forms and were stratified into four strata based on two factors: N3b versus non-N3b and abnormal lactate dehydrogenase (LDH) versus normal LDH. A permuted block randomization scheme with a block size of four was used to generate the randomization codes independently for each center and stratum.
Induction chemotherapy (MEPFL)
Patients randomised to the experimental arm received three cycles of MEPFL [7] before CCRT. MEPFL consisted of mitomycin 8 mg/m 2 , epirubicin 60 mg/m 2 , and cisplatin 60 mg/m 2 on D1, 5-FU 450 mg/m 2 , and leucovorin 30 mg/m 2 on D8. The cycle was repeated every 3 weeks if hemogram were adequate (leucocyte count !3500/ll and platelet count !100 000). If the leucocyte count was between 3000 and 3500/ll or the platelet count was between 75 000/ll and 100 000/ll on day 28, the dosage of mitomycin and epirubicin in the subsequent cycle was reduced by 20%.
RT and concomitant weekly cisplatin
Curative RT was initiated within 3 weeks after the registration or completion of the final cycle of MEPFL. Because the RT technique evolved from 3DCRT to IMRT at many Taiwanese centers during the study period, 140 (58%) of patients in the CCRT arm and 152 (64%) of those in the induction-CCRT (I-CCRT) arm received IMRT. The distribution was balanced in two arms. Patients receiving RT were administered 30 mg/m 2 cisplatin on a weekly basis, starting on the first day of RT. The details of CCRT are described in supplementary material, available at Annals of Oncology online.
Assessment and follow-up
NCI CTCAE v 3.0 was used to assess chemotherapy and acute radiation toxic effects. Late radiation toxic effects were assessed using the late radiation morbidity-scoring schema of the RTOG and EORTC. The tumor response was evaluated using physical examination, nasopharyngoscopy, and head and neck magnetic resonance imaging (MRI) 3 months after the completion of RT according to the WHO response criteria. After CCRT, patients were evaluated at least once every 3 months during the first 3 years and every 6 months thereafter. MRI and abdominal sonography were carried out annually at least or when tumor relapse was clinically suspected.
Data analysis and statistics, including interim analysis are detailed in supplementary material, available at Annals of Oncology online.
Results
Patient characteristics
From September 2003 to August 2009, 479 patients were enrolled from 11 institutes. Nine patients were ineligible after central review (Figure 1, CONSORT) . No significant difference in demographic characteristics was observed between the two arms ( Table  1) . Elevated LDH levels were observed in 11% of patients. The mean size of total tumor target lesions was 13.0 cm. Among 240 patients randomized to the CCRT arm, 227 received the assigned treatment. Among 239 patients assigned to the I-CCRT arm, 237 patients received the assigned treatment. Seven patients in the CCRT arm did not complete the treatment. In the I-CCRT arm, five patients did not complete induction treatment, and additional six patients did not complete CCRT ( Figure 1 ). The date of the last follow-up was on 9 October 2013. The range of follow-up period is between 0.1 and 108 months (the median was 72.0 months). 
Adverse effects and compliance
Induction phase. The acute toxicities during induction MEPFL are listed in Tables 2 and 3 . Grade 3/4 myelosuppression, particularly neutropenia, was the most common severe toxicity, and the incidence of grade 3 and 4 febrile neutropenia was 4% and 0.4%, respectively. One patient had grade 4 hepatotoxicity due to a hepatitis B flare up. The majority of the patients (199/237; 84%) completed the planned three cycles. Thirty-two patients completed two courses and six completed only one course, because of grade 4 vomiting or prolonged grade 2 nephrotoxicity.
Concurrent chemoradiotherapy. Tables 2 and 3 summarizes the grade 3/4 acute toxicities that occurred during CCRT. In the CCRT arm, the most common was mucositis (102/227; 45%).
Leucopenia was common but usually was grade 1/2. Nephrotoxicity was usually grade 1/2. In the I-CCRT arm, mucositis and myelosuppression were common toxicities. Those in the I-CCRT arm had a significantly higher risk of grade 3/4 leucopenia and thrombocytopenia (P<0.001, both). The risk of grade 3/4 dermatitis was similar in both arms. Two patients in the CCRT arm died during treatment because of upper GI bleeding and septic shock. Owing to the more severe myelotoxicity, fewer patients in the I-CCRT arm (26%) completed the planned concurrent cisplatin during RT than the CCRT arm (73%) (supplementary Table S1 , available at Annals of Oncology online; P<0.001). The dose intensity of cisplatin during radiation was 25.7 and 18.9 mg/m 2 /week for CCRT and I-CCRT arm, respectively (supplementary material, available at Annals of Oncology online).
The incidences of severe late toxicities are listed in supplementary Table S2 , available at Annals of Oncology online. Late radiation toxicities, including dry mouth, skin or mucosa atrophy, The table was calculated based on safety population in Figure 1 . P values were calculated with chi-square test or Fisher's exact test. The table was calculated based on safety population in Figure 1 . P values were calculated with chi-square test or Fisher's exact test.
trismus, and dysphagia, were common. Twenty-nine patients (13%) in the CCRT arm and 39 (17%) in the I-CCRT arm had grade 3 or 4 late toxicity; however, this difference was not statistically significant (P ¼ 0.2).
Response
Response was evaluated on eligible patients who took protocol treatment. In the CCRT arm, 3 months after CCRT completion, the complete response (CR) and partial response (PR) rates were 35% and 57%, respectively; with further follow-up, the CR and PR rates improved to 69% and 24%, respectively (supplementary Table S3 , available at Annals of Oncology online). In the I-CCRT arm, the CR and PR rates after induction were 5% and 72%, respectively. Three patients (1%) experienced disease progression. Three months after CCRT, the CR and PR rates changed to 57% and 37%, respectively. With longer follow-up, the CR rate further increased to 81%. The final overall response and CR rates were higher in the I-CCRT arm than in the CCRT arm, but only the difference of CR was significant (95% versus 93%; P ¼ 0.2 and 81% versus 69%; P ¼ 0.002, respectively).
Patterns of treatment failure
In the I-CCRT and CCRT arms, 41% (98 of 239) and 50% (121 of 240) of the patients exhibited recurrence. The first failure rates and accumulative failure rates are tabulated in supplementary  Table S4 , available at Annals of Oncology online. Distant metastasis was the most common first failure site in both arms. The I-CCRT arm had lower rates for local failure, regional failure, and distant metastases, but the difference was not significant.
Primary analysis
After stratified for N3b and LDH, and adjusted for the T stage, the I-CCRT arm had significantly higher DFS and locoregional DFS than those of the CCRT arm (DFS: 5-year rate, 61% versus 50%; adjusted HR¼0.739; 95% CI¼0.565-0.965; P ¼ 0.0264; Figure 2 and 3A. Locoregional failure-free survival: 5-year rate, 80% versus 70%; adjusted HR¼0.664; 95% CI¼0.459-0.960; P ¼ 0.0295; Figure 2B ). However, the distant failure-free survival and OS of the I-CCRT arm were not significantly different from those of the CCRT arm (distant failure-free survival: 5-year rate, 76% versus 71%; adjusted HR¼0.825; 95% CI¼0.580-1.172; P ¼ 0.2828; Figure 2C . OS: 5-year rate, 72% versus 68%; adjusted HR¼0.923; 95% CI¼0.671-1.270; P ¼ 0.624; Figure 2D ). The corresponding subgroup analysis and forest plot are shown in the supplement (supplementary Figure S1 , available at Annals of Oncology online).
Prognostic factors for recurrence or survival
In multivariate Cox proportional hazard regression analysis, the treatment group was a significant predictive factor for DFS and locoregional failure-free survival but not for distant failure-free survival and OS (Significant prognostic factors in multivariable Cox-regression analysis in Table 4 ; all prognostic factors in supplementary Table S5 , available at Annals of Oncology online). The performance status was a crucial factor predicting disease control and survival. N3b was a crucial predictive factor for distant control and OS, as expected; however, the T stage was not a crucial predictive factor. LDH level might be an independent prognostic factor for distant failure-free survival. However, the significance was marginal.
Discussion
Comparison of IC-CCRT trials-Is stage III locoregionally advanced?
The major difference from other published trials is the stage of patients recruited (supplementary Table S6 , available at Annals of Oncology online) [10] [11] [12] [13] . The survival of stage II and III are almost the same (American Cancer Society: Relative 5-year OS of stage II 64%, stage III 62%). A CCRT study had similar observation. For stage II, III and IV patients, the 3-year OS was 100%, 92.8%, and 69.4%, respectively [9] . The proportion of stage IVA-IVB is less than 50% in all reported studies (supplementary Table S6 , available at Annals of Oncology online). In contrast, 100% of patients in this study were stage IVA-IVB. Patients who received MEPFL had a response rate of 81%, higher than that of taxane-based therapy in two phase II trials (76% and 72%) [10, 11] . The incidence of severe myelosuppression was 59%, which is not higher than that obtained for taxane-based therapy [10, 11] , and was deemed tolerable viewing the low incidences of febrile neutropenia and infection (Tables 2 and 3 ). [14] . This is important as it could allow patients to avoid excessive treatment and toxicities.
The dose we used (30 mg/m 2 /week) also has been demonstrated to be effective for stage II NPC in a randomized trial [15] and the total proposed dose during the whole course is very close to 200 mg/ m 2 . The DFS and OS of CCRT arm of this study are not inferior and might be better, especially if considering stage IVA-B only (supplementary Table S6 , available at Annals of Oncology online).
Furthermore, we estimated the actual mean dose of cisplatin given in the CCRT arm and found that the dose given is very close for all studies (supplementary Table S6 , available at Annals of Oncology online). Even though 40 mg/m 2 /week was initially planned, the actual doses given were around 30 mg/m 2 /week due to limitation of toxicities.
No matter which regimen used for induction, the dose of cisplatin given during RT for IC-CCRT arm is lower than that of CCRT arm (supplementary Table S6 , available at Annals of Oncology online). Myelotoxicity of IC has not completely resolved during the RT period, and the incidences of severe leukopenia and thrombocytopenia were as high as 30% in this trial (Tables 2 and 3) , which led to a reduced dosage of cisplatin. All IC-CCRT arms yielded similar results, and this might imply a regimen-independent limitation of IC-CCRT and lower doseintensity during radiation may comprise the benefit of induction. 
RT technique
During the study period, the RT technique in many Taiwanese centers evolved from 3DCRT to IMRT. Although IMRT may provide greater local control and lower toxicities than 2DRT does, the local failure-free rate reached a plateau when 3DCRT was used, and the result for T4 remained unsatisfactory even with IMRT [16] . The proportions of patients receiving IMRT in the two arms of this study were well balanced, and in Cox multivariate analysis, the RT technique used was not a significant factor in all aspects of outcome analysis.
Which patients benefit from induction?
Two phase II studies of taxane-based regimens showed contradictory results [10, 11] . The Hong Kong study demonstrated the benefit of induction docetaxel and cisplatin for OS. In contrast, the HeCOG study revealed that 3 cycles of cisplatin, paclitaxel, and epirubicin followed by CCRT did not improve the response rate and survival [10] . The result of a phase II/III study in Singapore comparing neoadjuvant gemcitabine, carboplatin, and paclitaxel followed by CCRT or CCRT alone found no improvement in DFS and OS [13] . Sun's study concluded that modified TPF significantly improved DFS and OS in LANPC [12] . Though OS is improved mainly by reduction of distant metastasis but this benefit was noted only in patients with N1 disease. The benefit of induction could not be seen in N2-N3b disease [12] . Our study clearly demonstrated that induction MEPFL improved the 5-year DFS in stage IVA-IVB. So far, this is the only positive result for this highest risk group (supplementary Table S6 , available at Annals of Oncology online).
Perspectives
This study demonstrated that MEPFL before CCRT in patients with stage IVA-IVB increases DFS, mainly through enhanced locoregional control; however, distant metastasis was not significantly reduced. Selection of a high-risk group but not those with occult M1 disease (by staging PET/CT) [17] should be a vital consideration in design of future trial for LANPC. Furthermore, IC-CCRT is limited by myelotoxicity, which persists from the induction phase to the RT period and may compromise the therapeutic effect of CCRT. Tumors also could evolve to become more chemoresistant when the disease progresses to more advanced stages. Therefore, new approaches that combine different modalities may be the next step in overcoming the problem of distant metastasis.
